Prostate cancer risk variants are not associated with disease progression

Currently used prognostic markers are limited in their ability to accurately predict disease progression among patients with localized prostate cancer. We examined 23 reported prostate cancer susceptibility variants for association with disease progression.

[1]  A. Partin,et al.  ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. , 2011, Urology.

[2]  F. Wiklund.  Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers? , 2010, Genome Medicine.

[3]  J. Witte,et al.  Prostate Cancer Susceptibility Variants Confer Increased Risk of Disease Progression , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[4]  Pär Stattin,et al.  Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study , 2010, Journal of the National Cancer Institute.

[5]  Jianfeng Xu,et al.  Prostate cancer risk‐associated variants reported from genome‐wide association studies: Meta‐analysis and their contribution to genetic Variation , 2010, The Prostate.

[6]  Janet L Stanford,et al.  Association of hepsin gene variants with prostate cancer risk and prognosis , 2010, The Prostate.

[7]  Douglas F Easton,et al.  Genome-wide association studies in common cancers--what have we learnt? , 2010, Current opinion in genetics & development.

[8]  D. Penson,et al.  Health related quality of life for men treated for localized prostate cancer with long-term followup. , 2010, The Journal of urology.

[9]  P. Scardino,et al.  Susceptibility Loci Associated with Prostate Cancer Progression and Mortality , 2010, Clinical Cancer Research.

[10]  Sudhir Srivastava,et al.  A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [−2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[11]  L. Klotz.  Active Surveillance for Prostate Cancer: A Review , 2010, Current urology reports.

[12]  Hong-Zin Lee,et al.  Prognostic Significance of Prostate Cancer Susceptibility Variants on Prostate-Specific Antigen Recurrence after Radical Prostatectomy , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[13]  H. Grönberg,et al.  Macrophage Inhibitory Cytokine 1: A New Prognostic Marker in Prostate Cancer , 2009, Clinical Cancer Research.

[14]  B. Trock,et al.  Individual and cumulative effect of prostate cancer risk‐associated variants on clinicopathologic variables in 5,895 prostate cancer patients , 2009, The Prostate.

[15]  Peter Kraft,et al.  Toll-like Receptor Signaling Pathway Variants and Prostate Cancer Mortality , 2009, Cancer Epidemiology Biomarkers & Prevention.

[16]  P. Kantoff,et al.  Evaluation of 8q24 and 17q Risk Loci and Prostate Cancer Mortality , 2009, Clinical Cancer Research.

[17]  H. Grönberg,et al.  Established Prostate Cancer Susceptibility Variants are not Associated with Disease Outcome , 2009, Cancer Epidemiology Biomarkers & Prevention.

[18]  Y. Fradet.  Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen , 2009, Current opinion in urology.

[19]  J. Stanford,et al.  CYP17 polymorphisms and prostate cancer outcomes , 2009, The Prostate.

[20]  H. Grönberg,et al.  Genetic variation in the upstream region of ERG and prostate cancer , 2009, Cancer Causes & Control.

[21]  L. Holmberg,et al.  The completeness of the Swedish Cancer Register – a sample survey for year 1998 , 2009, Acta oncologica.

[22]  P. Stattin,et al.  Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. , 2008, The Journal of urology.

[23]  K. Hemminki,et al.  Survival in bladder and renal cell cancers is familial. , 2008, Journal of the American Society of Nephrology : JASN.

[24]  Shahrokh F. Shariat,et al.  Inventory of prostate cancer predictive tools , 2008, Current opinion in urology.

[25]  K. Hemminki,et al.  Concordance of survival in family members with prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Kevin M. Bradley,et al.  Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer , 2008, Nature Genetics.

[27]  Ali Amin Al Olama,et al.  Multiple newly identified loci associated with prostate cancer susceptibility , 2008, Nature Genetics.

[28]  W. Willett,et al.  Multiple loci identified in a genome-wide association study of prostate cancer , 2008, Nature Genetics.

[29]  J. Carpten,et al.  Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. , 2007, Journal of the National Cancer Institute.

[30]  K. Czene,et al.  Familial concordance in cancer survival: a Swedish population-based study. , 2007, The Lancet. Oncology.

[31]  H. Grönberg,et al.  Inherited Variation in Hormone-Regulating Genes and Prostate Cancer Survival , 2007, Clinical Cancer Research.

[32]  D. Gudbjartsson,et al.  Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes , 2007, Nature Genetics.

[33]  K. Czene,et al.  Is breast cancer prognosis inherited? , 2007, Breast Cancer Research.

[34]  Alan W Partin,et al.  Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. , 2007, Urology.

[35]  C. Bermejo,et al.  Management of the complications of radical prostatectomy , 2007, Current urology reports.

[36]  P. Fearnhead,et al.  Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 , 2007, Nature Genetics.

[37]  D. Gudbjartsson,et al.  Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24 , 2007, Nature Genetics.

[38]  L. Holmberg,et al.  Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005 , 2007, Scandinavian journal of urology and nephrology.

[39]  A. Whittemore,et al.  Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men , 2006, Proceedings of the National Academy of Sciences.

[40]  A. Gylfason,et al.  A common variant associated with prostate cancer in European and African populations , 2006, Nature Genetics.